Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Diagnostic Microbiology and Infectious Disease
|
February 1, 1995
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group
R N Jones, H S Sader, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
February 1, 1992
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum
M S Barrett, R N Jones, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
July 1, 1994
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates
F P Koontz, M E Erwin, M S Barrett, et al.
Diagnostic Microbiology and Infectious Disease
|
August 1, 1994
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group
R N Jones, E N Kehrberg, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
October 1, 1993
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials
R N Jones, M E Erwin, H L Hager, et al.
Journal of Chemotherapy (Florence, Italy)
|
October 1, 1991
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci
R N Jones, D M Johnson, M S Barrett, et al.
Journal of Clinical Microbiology
|
December 1, 1993
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates
J H Hughes, D J Biedenbach, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
March 1, 1996
Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis
M G Cormican, M E Erwin, S A Marshall, et al.
Diagnostic Microbiology and Infectious Disease
|
April 1, 1994
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards
R N Jones, G V Doern, E H Gerlach, et al.
Antimicrobial Agents and Chemotherapy
|
September 1, 1992
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates
B B Gooding, M E Erwin, M S Barrett, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Diagnostic Microbiology and Infectious Disease
|
February 1, 1995
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group
R N Jones, H S Sader, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
February 1, 1992
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum
M S Barrett, R N Jones, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
July 1, 1994
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates
F P Koontz, M E Erwin, M S Barrett, et al.
Diagnostic Microbiology and Infectious Disease
|
August 1, 1994
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group
R N Jones, E N Kehrberg, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
October 1, 1993
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials
R N Jones, M E Erwin, H L Hager, et al.
Journal of Chemotherapy (Florence, Italy)
|
October 1, 1991
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci
R N Jones, D M Johnson, M S Barrett, et al.
Journal of Clinical Microbiology
|
December 1, 1993
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates
J H Hughes, D J Biedenbach, M E Erwin, et al.
Diagnostic Microbiology and Infectious Disease
|
March 1, 1996
Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis
M G Cormican, M E Erwin, S A Marshall, et al.
Diagnostic Microbiology and Infectious Disease
|
April 1, 1994
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards
R N Jones, G V Doern, E H Gerlach, et al.
Antimicrobial Agents and Chemotherapy
|
September 1, 1992
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates
B B Gooding, M E Erwin, M S Barrett, et al.
Page
of 9